Skip to content
Fredun Pharmaceuticals logo

Fredun Pharmaceuticals

FREDUN NSE
₹1,455.00 down 17.20 (1.17%)
Market Cap
₹2,406 Cr
P/E
51.80

Fredun Pharmaceuticals (FREDUN) share price was ₹1,472.20 at the 28 Oct 2026 close; market capitalisation ₹2,435 Cr; P/E (TTM) 52.41; sector Healthcare. In the Jun 2026 quarter, revenue rose 90.4% year on year to ₹228.3 Cr and net profit was ₹13 Cr, against ₹7 Cr a year earlier (compared with Jun 2025). Promoters held 43.62% of Fredun Pharmaceuticals in Sep 2026, down 0.95 percentage points from Jun 2026. Its Tapetide Score is 42/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹1,472.20 +478.40 +48.14% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹2,406 Cr
P/E (TTM)
51.8
EBITDA
₹94.50 Cr
Return on Equity
11.73%
Debt to Equity
0.8
Book Value
₹200.11
EPS (TTM)
₹28.09
52W High
₹1,665.00
52W Low
₹1,195.20

Price-based figures as of 29 Oct 2026, 10:57 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.5035.044,23,843 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,635.0087.452,55,779 Cr15.260.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,598.4072.191,74,908 Cr9.520.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,184.70107.941,18,042 Cr22.270.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,180.5026.271,17,755 Cr4.340.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,341.0034.731,11,931 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,370.5032.831,10,717 Cr3.130.96%11.21%14.88%28,589 Cr3,356 Cr
Fredun Pharmaceuticals (this company)
₹1,458.0051.902,411 Cr7.290.05%11.73%25.00%742 Cr44 Cr
Median 8 companies₹1,612.2543.471,17,899 Cr6.180.47%12.98%18.45%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

42 Weak
Overall score

Data confidence 100/100

Category scores

Quality Average 50
Returns, margins, earnings quality 22% weight
Valuation Poor 30
Cheap vs sector & own history 24% weight
Growth Strong 99
Sales & profit trajectory 9% weight
Financial Health Poor 32
Solvency, leverage, coverage 9% weight
Momentum Poor 17
Trend strength, vol-adjusted 12% weight
Ownership Poor 36
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

4
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 75.2% CAGR over last 5 years
  • Debtor days have improved from 87.9 to 53.2 days.
  • Company's median sales growth is 28.6% of last 10 years

Weaknesses

2
  • Stock is trading at 8.67 times its book value
  • Promoter holding has decreased over last 3 years: -4.74%

Technical Indicators

Oscillators

Bearish

Bearish
2
Neutral
7
Bullish
0

Overall

Neutral

Bearish
6
Neutral
7
Bullish
6

Moving Averages

Bullish

Bearish
4
Neutral
0
Bullish
6

Growth Rate

Revenue Growth
40.06% higher than 3Y

change over 1 year

Net Income Growth
65.48% higher than 3Y

change over 1 year

Cash Flow Change
172%

change over 1 year

EBITDA Margin Change
22.94%

change over 1 year Operating margin 14% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
62
82
87
118
79
107
103
167
120
145
161
213
228
Expenses
54
72
76
107
68
93
89
150
103
123
135
184
195
Operating Profit
8
10
11
11
10
14
13
17
17
22
26
29
33
OPM %
12%
12%
12%
9%
13%
13%
13%
10%
14%
15%
16%
14%
14%
Other Income
0
0
0
0
0
0
0
0
0
0
0
0
0
Interest
3
3
4
4
4
5
5
8
7
8
11
14
9
Depreciation
1
1
1
1
1
1
1
1
1
2
2
3
4
PBT
4
6
6
6
6
8
7
8
9
13
14
12
21
Tax %
41%
32%
27%
13%
25%
44%
25%
12%
25%
25%
25%
4%
36%
Net Profit
2
4
4
5
4
4
5
7
7
10
10
11
13
EPS (₹)
1.75
2.79
2.99
3.59
2.91
3.01
3.75
4.98
4.77
6.85
6.51
6.75
7.98
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
25
42
57
60
97
113
134
222
275
348
454
635
748
Expenses
24
38
53
54
87
104
126
208
247
310
401
544
637
Operating Profit
2
4
3
6
10
8
8
14
28
38
53
91
111
OPM %
7%
9%
6%
10%
11%
7%
6%
6%
10%
11%
12%
14%
15%
Other Income
0
1
2
0
0
1
1
2
2
1
2
4
0
Interest
1
2
2
2
3
4
4
5
9
14
22
39
41
Depreciation
1
1
1
1
1
2
2
2
3
4
4
8
10
PBT
1
2
2
3
6
2
3
9
18
21
28
48
59
Tax %
52%
42%
36%
34%
28%
24%
37%
26%
38%
27%
26%
30%
—
Net Profit
0
1
1
2
4
2
2
6
11
16
21
33
44
EPS (₹)
0.37
1.51
2.01
1.7
3.72
1.58
1.68
4.77
7.95
11.08
14.65
20.25
28.09
Div. Payout %
0%
13%
10%
12%
6%
14%
14%
5%
3%
2%
2%
1%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
2
2
2
3
4
4
4
4
5
5
5
5
Reserves
0
1
2
19
35
37
39
64
92
117
137
273
Borrowings
9
16
21
10
19
35
40
53
87
106
166
222
Other Liabilities
11
24
30
47
47
65
79
66
74
81
179
141
Total Liabilities
23
43
56
79
105
141
162
187
257
308
487
642
Fixed Assets
8
15
16
16
31
31
30
32
39
47
53
118
CWIP
1
0
4
11
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
1
2
2
Other Assets
14
29
36
52
74
110
131
155
218
260
433
522
Total Assets
23
43
56
79
105
141
162
187
257
308
487
642
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
2
3
4
17
1
-11
0
-2
-14
0
-21
16
Investing
-3
-6
-7
-8
-5
-1
-1
-4
-9
-8
-6
-74
Financing
1
3
3
-8
4
14
-1
7
25
6
26
122
Net Cash Flow
0
1
-1
1
0
2
-2
1
1
-2
-1
65
Free Cash Flow
-1
-3
-3
9
-4
-12
-1
-7
-24
-8
-27
-57
CFO/OP
108
85
117
303
8
-128
2
-17
-52
-1
-43
18
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
75
98
131
94
67
126
112
148
46
68
142
53
Inventory Days
102
140
68
170
249
227
242
96
264
246
267
219
Days Payable
167
221
224
360
205
208
215
101
104
88
161
71
Cash Conversion Cycle
11
17
-24
-96
110
145
139
144
205
225
248
201
Working Capital Days
-54
-44
-39
42
66
65
116
126
97
92
76
79
ROCE %
14%
25%
18%
16%
21%
10%
10%
13%
18%
17%
19%
21%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Fredun Pharmaceuticals insights

67 extracted metrics + investor summaries across FY07–FY27.

Shareholding Pattern

FIIs0.69%Promot.43.62%DIIs3.44%Others9.01%Public43.24%As ofSep 2026

Documents

Frequently Asked Questions about Fredun Pharmaceuticals

What does Fredun Pharmaceuticals Ltd do?
Incorporated in 1987, Fredun Pharmaceuticals Ltd manufactures & exports healthcare and pharmaceuticals products[1]
Where is Fredun Pharmaceuticals Ltd (FREDUN) listed?
Fredun Pharmaceuticals Ltd trades as FREDUN on the NSE and under code 539730 on the BSE.
Which sector does Fredun Pharmaceuticals Ltd belong to?
Fredun Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Fredun Pharmaceuticals Ltd?
Fredun Pharmaceuticals Ltd has a market capitalisation of ₹2,406 Cr as of 29 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Fredun Pharmaceuticals Ltd?
Fredun Pharmaceuticals Ltd trades at a PE ratio of 51.80 as of 29 Oct 2026, on earnings per share of ₹28.09, against a book value of ₹200.11 per share.
What is the 52-week high and low of Fredun Pharmaceuticals Ltd?
Over the last 52 weeks Fredun Pharmaceuticals Ltd has traded between ₹1,195.2 and ₹1,665 as of 29 Oct 2026.
Does Fredun Pharmaceuticals Ltd pay dividends?
Fredun Pharmaceuticals Ltd has a dividend yield of 0.05%.
What is the Return on Equity (ROE) of Fredun Pharmaceuticals Ltd?
Fredun Pharmaceuticals Ltd reported a return on equity of 11.73%. Its debt-to-equity ratio is 0.80.

Company Information

Incorporated in 1987, Fredun Pharmaceuticals Ltd manufactures & exports healthcare and pharmaceuticals products[1]

Website fredungroup.com
Listed 2016-03-28
Face Value ₹ 10
Shares Outstanding 1,65,38,070

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/539730.md for Fredun Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month